Evidence map›Paper›PMID 24422098›Full record

ArticleBoneKEy reports2013

Tumour cells coerce host tissue to cancer spread.

Ilaria Malanchi

Abstract read
In one paragraph

Article in BoneKEy reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition.Cellular oncology (Dordrecht, Netherlands) · 2019
    Review
  3. Far-reaching effects from carbon nanotubes.Nature nanotechnology · 2019
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ilaria MalanchiCancer Research UK, London Research Institute , 44 Lincolns Inn Fields, London , UK.

Funding

Cancer Research UK 14257
6 · The paper itself

Abstract

A solid tumour is a complex structure and understanding this complexity is required to study the disease progression. Indeed, 90% of cancer deaths are due to metastatic spreading. Two aspects contribute to tumour complexity. One is the synergistic relationship between tumour cells and their associated host tissue, which persistently characterize tumour growth from the onset to metastasis. Another aspect is the heterogeneity of the cancer cells. It is now clear that within a tumour mass there is a hierarchical organization, stemming from a small amount of cells retaining the highest tumorigenic potential, named cancer stem cells (CSCs). Despite being one of the main studied topics in cancer research, CSC definition is still the subject of debate. Functional testing allows their identification, which is the ability of recapitulating the original tumour structure when transplanted in mice, but occasionally generates conflicting results. This has shaped the hypothesis that their key initiation ability is conditioned by their local microenvironment called niche. The CSC identity appears to be a contextual status where the ability to create a favourable supporting microenvironment may become a key hallmark of their tumour initiation capability. Remarkably, as shown in experimental models, the tumour-initiating potential of CSCs is maintained during metastatic progression, when disseminated cancer cells require the creation of their permissive niche to be able to trigger metastatic growth. This review will discuss the most recent findings on metastatic niche establishment and the cooperation between cancer cells and their newly recruited tumour-associated stroma forming the basis of metastatic development.

Identifiers

PMID24422098
PMCPMC3817981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.